Poulton Jeffrey V.'s Form 4 filing
Alnylam Pharmaceuticals, Inc. (ALNY) · filed Aug 19, 2025
- Accession no.
- 0001735276-25-000090
- Filed
- Aug 19, 2025
- Trade date
- Aug 15-18, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 9 non-derivative transactions and 0 derivative transactions. Open-market sales total $1.03M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Poulton Jeffrey V.CIK 0001782962 | Officer (EVP, Chief Financial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 15, 2025 | Common Stock | AGrant or awardAcquired | +4,644 | $0.00 | $0 | 52,395 | Direct | |
| Aug 18, 2025 | Common Stock | SSaleDisposed | −63 | $447.98 | −$28,222.74 | 52,332 | Direct | |
| Aug 18, 2025 | Common Stock | SSaleDisposed | −147 | $449.92 | −$66,138.24 | 52,185 | Direct | |
| Aug 18, 2025 | Common Stock | SSaleDisposed | −63 | $450.92 | −$28,407.96 | 52,122 | Direct | |
| Aug 18, 2025 | Common Stock | SSaleDisposed | −168 | $451.99 | −$75,934.32 | 51,954 | Direct | |
| Aug 18, 2025 | Common Stock | SSaleDisposed | −536 | $452.96 | −$242,786.56 | 51,418 | Direct | |
| Aug 18, 2025 | Common Stock | SSaleDisposed | −886 | $454.04 | −$402,279.44 | 50,532 | Direct | |
| Aug 18, 2025 | Common Stock | SSaleDisposed | −392 | $454.84 | −$178,297.28 | 50,140 | Direct | |
| Aug 18, 2025 | Common Stock | SSaleDisposed | −19 | $455.82 | −$8,660.58 | 50,121 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.